Special Issue

Molecular Imaging of the Tumor Microenvironment

Message from the Guest Editor

With the progress in research, we all acknowledge that treating cancer involves focusing on cancer cells and understanding their interactions with the surrounding cells and extracellular matrix, which compose the tumor microenvironments (TME). Immunotherapies have recently shown promising results in various types of cancers, and the concept of the tumor microenvironment has expanded to include immunerelated components such as immune cells and cytokines. Consequently, a new field of research called the tumor immune microenvironment (TIME) has been proposed and actively explored. Traditionally, many animals have to be used to study specific events occurring in the TME/TIME because they need to be sacrificed to conduct different experiments. However, with the emergence and utilization of molecular imaging in biomedical research, disease progression and interactions between multiple cell types or overall tumor microenvironmental changes can be tracked employing various imaging instruments noninvasively at multiple time points using the same cohort of animals. We welcome original research articles, editorials and review articles.

Guest Editor

Dr. Hui-Yen Chuang

Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan

Deadline for manuscript submissions

closed (15 June 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/195574

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

